B-cell prolymphocytic leukemia pathophysiology: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
Line 4: Line 4:


== Overview ==
== Overview ==
B-cell prolymphocytic leukemia arises from mature B-cells, which are hematologic white cells that are normally involved in the in the [[humoral immunity]] component of the adaptive immune system by secreting [[antibodies]].
[[B cell|B-cell]] [[prolymphocytic leukemia]] arises from mature [[B-cells]], which are [[Hematology|hematologic]] [[white cells]] that are normally involved in the in the [[humoral immunity]] component of the [[adaptive immune system]] by secreting [[antibodies]].


==Pathophysiology==
==Pathophysiology==
Line 10: Line 10:


===Markers===
===Markers===
*B-cell prolymphocytic leukemia cells are positive for B cell maerkers such as [[CD19]], [[CD20]], [[CD22]].<ref name="pmid9657013">{{cite journal |author=Yamamoto K, Hamaguchi H, Nagata K, Shibuya H, Takeuchi H |title=Splenic irradiation for prolymphocytic leukemia: is it preferable as an initial treatment or not? |journal=Jpn. J. Clin. Oncol. |volume=28 |issue=4 |pages=267–9 |date=April 1998 |pmid=9657013 |doi= 10.1093/jjco/28.4.267|url=http://jjco.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=9657013}}</ref>
*[[B cell|B-cell]] [[prolymphocytic leukemia]] cells are positive for [[B cell|B cell markers]] such as [[CD19]], [[CD20]], [[CD22]].<ref name="pmid9657013">{{cite journal |author=Yamamoto K, Hamaguchi H, Nagata K, Shibuya H, Takeuchi H |title=Splenic irradiation for prolymphocytic leukemia: is it preferable as an initial treatment or not? |journal=Jpn. J. Clin. Oncol. |volume=28 |issue=4 |pages=267–9 |date=April 1998 |pmid=9657013 |doi= 10.1093/jjco/28.4.267|url=http://jjco.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=9657013}}</ref>
*[[CD23]] is negative but [[CD5]] is expressed in one third tumor cells population.<ref name="urlPathology">{{cite web |url=http://www.med-ed.virginia.edu/courses/path/innes/wcd/lympleuk.cfm |title=Pathology |format= |work= |accessdate=2009-01-31| archiveurl= http://web.archive.org/web/20090207235133/http://www.med-ed.virginia.edu/courses/path/innes/wcd/lympleuk.cfm| archivedate= 7 February 2009 <!--DASHBot-->| deadurl= no}}</ref><ref name="pmid24759024">{{cite journal |vauthors=Yi S, Li Z, Wang H, Liu W, Lyu R, Yu Z, Qi J, Qiu L |title=[The immunophenotypic characteristics of 260 patients with CD5 + B cell lymphoproliferative disorders] |language=Chinese |journal=Zhonghua Xue Ye Xue Za Zhi |volume=35 |issue=4 |pages=337–41 |date=April 2014 |pmid=24759024 |doi=10.3760/cma.j.issn.0253-2727.2014.04.019 |url=}}</ref>
*[[CD23]] is negative but [[CD5]] is expressed in one third [[tumor]] cells population.<ref name="urlPathology">{{cite web |url=http://www.med-ed.virginia.edu/courses/path/innes/wcd/lympleuk.cfm |title=Pathology |format= |work= |accessdate=2009-01-31| archiveurl= http://web.archive.org/web/20090207235133/http://www.med-ed.virginia.edu/courses/path/innes/wcd/lympleuk.cfm| archivedate= 7 February 2009 <!--DASHBot-->| deadurl= no}}</ref><ref name="pmid24759024">{{cite journal |vauthors=Yi S, Li Z, Wang H, Liu W, Lyu R, Yu Z, Qi J, Qiu L |title=[The immunophenotypic characteristics of 260 patients with CD5 + B cell lymphoproliferative disorders] |language=Chinese |journal=Zhonghua Xue Ye Xue Za Zhi |volume=35 |issue=4 |pages=337–41 |date=April 2014 |pmid=24759024 |doi=10.3760/cma.j.issn.0253-2727.2014.04.019 |url=}}</ref>
*Another case was described as [[CD45]]+, [[CD19]]+, [[CD20]]+, [[CD5]]+, [[HLA-DR]]+, [[CD10]]-, [[CD23]]+/-, [[CD38]]+ and [[FMC7]]<ref name="pmid16997373">{{cite journal |author=Crisostomo RH, Fernandez JA, Caceres W |title=Complex karyotype including chromosomal translocation (8;14) (q24;q32) in one case with B-cell prolymphocytic leukemia |journal=Leuk. Res. |volume=31 |issue=5 |pages=699–701 |date=May 2007 |pmid=16997373 |doi=10.1016/j.leukres.2006.06.010 |url=http://linkinghub.elsevier.com/retrieve/pii/S0145-2126(06)00218-9}}</ref>
*Another case was described as [[CD45]]+, [[CD19]]+, [[CD20]]+, [[CD5]]+, [[HLA-DR]]+, [[CD10]]-, [[CD23]]+/-, [[CD38]]+ and [[FMC7]]<ref name="pmid16997373">{{cite journal |author=Crisostomo RH, Fernandez JA, Caceres W |title=Complex karyotype including chromosomal translocation (8;14) (q24;q32) in one case with B-cell prolymphocytic leukemia |journal=Leuk. Res. |volume=31 |issue=5 |pages=699–701 |date=May 2007 |pmid=16997373 |doi=10.1016/j.leukres.2006.06.010 |url=http://linkinghub.elsevier.com/retrieve/pii/S0145-2126(06)00218-9}}</ref>
*Tumor cells express surface IgM proteins.
*Tumor cells express surface IgM proteins.
Line 23: Line 23:
==References==
==References==
{{reflist|2}}
{{reflist|2}}


[[Category:Leukemia]]
[[Category:Leukemia]]

Revision as of 14:35, 5 April 2019

B-cell prolymphocytic leukemia

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating B-cell prolymphocytic leukemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Biopsy

X Ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

B-cell prolymphocytic leukemia pathophysiology On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of B-cell prolymphocytic leukemia pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on B-cell prolymphocytic leukemia pathophysiology

CDC on B-cell prolymphocytic leukemia pathophysiology

B-cell prolymphocytic leukemia pathophysiology in the news

Blogs on B-cell prolymphocytic leukemia pathophysiology

Directions to Hospitals Treating B-cell prolymphocytic leukemia

Risk calculators and risk factors for B-cell prolymphocytic leukemia pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Qurrat-ul-ain Abid, M.D.[2],Carlos A Lopez, M.D. [3]

Overview

B-cell prolymphocytic leukemia arises from mature B-cells, which are hematologic white cells that are normally involved in the in the humoral immunity component of the adaptive immune system by secreting antibodies.

Pathophysiology

Markers

Microscopic pathology

  • The originating cell line for B-cell prolymphocytic leukemia is a mature B-cells and are medium sized cells.
  • More than 50 percent of the circulating cells in the peripheral blood are prolymphocytes.
  • The nucleus is typically round or oval, and the cytoplasm is usually moderately abundant.
  • Leukemic cells can be found in peripheral blood, lymph nodes, bone marrow, spleen, liver, and skin.[5]

References

  1. ↑ Yamamoto K, Hamaguchi H, Nagata K, Shibuya H, Takeuchi H (April 1998). "Splenic irradiation for prolymphocytic leukemia: is it preferable as an initial treatment or not?". Jpn. J. Clin. Oncol. 28 (4): 267–9. doi:10.1093/jjco/28.4.267. PMID 9657013.
  2. ↑ "Pathology". Archived from the original on 7 February 2009. Retrieved 2009-01-31.
  3. ↑ Yi S, Li Z, Wang H, Liu W, Lyu R, Yu Z, Qi J, Qiu L (April 2014). "[The immunophenotypic characteristics of 260 patients with CD5 + B cell lymphoproliferative disorders]". Zhonghua Xue Ye Xue Za Zhi (in Chinese). 35 (4): 337–41. doi:10.3760/cma.j.issn.0253-2727.2014.04.019. PMID 24759024.
  4. ↑ Crisostomo RH, Fernandez JA, Caceres W (May 2007). "Complex karyotype including chromosomal translocation (8;14) (q24;q32) in one case with B-cell prolymphocytic leukemia". Leuk. Res. 31 (5): 699–701. doi:10.1016/j.leukres.2006.06.010. PMID 16997373.
  5. ↑ Stone RM (April 1990). "Prolymphocytic leukemia". Hematol. Oncol. Clin. North Am. 4 (2): 457–71. PMID 2182602.
Retrieved from "https://www.wikidoc.org/index.php?title=B-cell_prolymphocytic_leukemia_pathophysiology&oldid=1561524"